---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-081265"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:38:06.886580+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics receives FDA IND clearance for Phase 1b/2a study of briquilimab in chronic spontaneous urticaria

## Summary
- FDA cleared IND for Phase 1b/2a repeat dose study of subcutaneous briquilimab in CSU patients.
- First patient expected by end of 2023; early data from initial cohorts by mid-2024.
- Separate CIndU proof-of-concept study to start Q1 2024 with initial data by year-end 2024.
- Study enrolls ~40 patients across 6 cohorts; primary endpoints safety/tolerability, secondary efficacy/PK.
- Targets CSU patients ineligible for or refractory to omalizumab, a high unmet need population.

## SEC filing metadata
- accession: 0001213900-23-081265
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023081265/0001213900-23-081265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023081265/ea186487-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-081265
- JSON: https://secwatch.observer/filing/0001213900-23-081265.json
- Plain text: https://secwatch.observer/filing/0001213900-23-081265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.